US IRB approval of Collategene trial boosts AnGes
This article was originally published in Scrip
Shares in AnGes MG spiked in Tokyo after the Japanese bioventure announced its US subsidiary had received final institutional review board (IRB) approval for a planned pilot trial with the firm's lead therapeutic candidate.
You may also be interested in...
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
A resolution in a long-running patent dispute, expansion of coronavirus vaccine production, drug development trends over the past decade, hematological malignancies in a clinical trial, and the last instalment in the Scrip Asks series all feature in this week's podcast version of Scrip's Five Must-Know Things.
US research-based association says move to annual drug repricing undermines country’s recent efforts to support innovation and again calls for inclusive discussions around broad health system reforms to create funding headroom.